Nicotinamide Mononucleotide (NMN)

Nicotinamide Mononucleotide (NMN) is a nucleotide derivative that has gained significant attention in longevity research as a precursor to NAD+, a coenzyme essential for cellular energy production and DNA repair. Research suggests that NAD+ levels naturally decline with age, and studies indicate NMN supplementation may help restore these levels, potentially supporting various cellular functions associated with healthy aging.

Preliminary human studies suggest NMN supplementation may influence muscle metabolism, insulin sensitivity, and mitochondrial function, though most research has been conducted in small populations over relatively short periods. Animal studies have shown more dramatic effects on lifespan and age-related markers, but translation to human benefits remains under investigation. The supplement has shown a good safety profile in completed trials, with minimal reported side effects.

While research is promising, the field is still developing with most human studies being small-scale and short-term. The regulatory status of NMN varies by jurisdiction, with some uncertainty in the US market following FDA's 2022 decision to exclude it from the dietary supplement category due to ongoing drug development research. Consumers interested in NMN should be aware of these regulatory considerations and the evolving nature of the research landscape.